登录新浪财经APP 搜索【信披】查看更多考评等级 质量负责人：罗贵全 有效期至：2030年7月17日 编 号：川20160226 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 恩威医药股份有限公司（以下简称"公司"）全资子公司四川恩威制药有限公司（以下简称：四川恩威） 于近日取得了药品监管部门换发的《药品生产许可证》，现将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 企业名称：四川恩威制药有限公司 注册地址：四川省成都市双流区双华路三段458号 社会信用代码：91510100777458424P 法定代表人：庄严 企业负责人：庄严 四川省成都市双流区双华路三段458号：软膏剂，洗剂，颗粒剂，片剂，硬胶囊剂，栓剂，合剂，软胶 囊剂，直接口服饮片，中药前处理和提取*** 二、药品生产许可证副本变更情况 同意该企业委托湖南泰阳药业有限公司生产姜脑止痛搽剂（国药准字国药准字B20020998），分类码 由"AhzyCz"变更为"AhzyBzCz"；其他内容不变。 分类码：AhzyBzCz 三、补充说明及对公司的影响 生产地址和生产范围： 1、姜脑止痛搽剂 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2026-007 恩威医药股份有限公司关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 恩威医药股份有限公司（以下简称"公司"）全资子公司四川恩威制药有限公司（以下简称：四川恩威） 于近日取得了药品监管部门换发的《药品生产许可证》，现将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 企业名称：四川恩威制药有限公司 有效期至：2030年7月17日 编 号：川20160226 分类码：AhzyBzCz 注册地址：四川省成都市双流区双华路三段458号 社会信用代码：91510100777458424P 法定代表人：庄严 企业负责人：庄严 质量负责人：罗贵全 1、姜脑止痛搽剂委托生产药品生产许可证变更与GMP符合性检查已办理完毕，尚需受托方湖南泰阳药 业有限公司办理该品种受托生产药品许可证变更、四川恩威完成该品种再注册后方能投入生产； 2、姜脑止痛搽剂是公司独家的中成药产品，具有散寒止痛，通络除湿的功效，适用 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-007 恩威医药股份有限公司 关于全资子公司取得换发的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司（以下简称"公司"）全资子公司四川恩威制药有限公司 （以下简称：四川恩威）于近日取得了药品监管部门换发的《药品生产许可证》，现 将有关情况公告如下： 一、换发的《药品生产许可证》基本信息 企业名称：四川恩威制药有限公司 注册地址：四川省成都市双流区双华路三段 458 号 社会信用代码：91510100777458424P 有效期至：2030 年 7 月 17 日 编 号：川 20160226 分类码：AhzyBzCz 生产地址和生产范围： 法定代表人：庄严 企业负责人：庄严 质量负责人：罗贵全 四川省成都市双流区双华路三段 458 号：软膏剂，洗剂，颗粒剂，片剂，硬胶囊 剂，栓剂，合剂，软胶囊剂，直接口服饮片，中药前处理和提取*** 二、药品生产许可证副本变更情况 同意该企业委托湖南泰阳药业有限公司生产姜脑止痛搽剂（国药准字国药准字 B20020998 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-006 恩威医药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股 东成都恩威投资（集团）有限公司（以下简称"恩威集团"）函告，获悉恩威集 团所持本公司的部分股份被办理了解除质押。恩威集团为公司控股股东，持有公 司 25,733,200 股，占公司总股本的 25.01%。具体事项如下： 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为 26,390,836 股，占其所持公司股份的 39.33%，占公司总股本的 25.65%，对应融 资余额为 28,400 万元；未来一年内到期的累计质押股份数量为 45,730,836 股， 占其所持公司股份的 68.15%，占公司总股本的 44.45%，对应融资余额为 47,300 万元。公司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自 筹资金。 3、截至本公告披露日，上述股东及其一致行动人不存在非 ...

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Group 1 - The controlling shareholder, Chengdu Enwei Investment (Group) Co., Ltd., has partially lifted the pledge on its shares in Enwei Pharmaceutical Co., Ltd., holding 25,733,200 shares, which accounts for 25.01% of the total share capital [2] - As of the announcement date, the total pledged shares by the shareholder and its concerted parties exceed 50% of their holdings, with 28,080,836 shares maturing in the next six months, representing 41.85% of their holdings and 27.29% of the total share capital, with a corresponding financing balance of 30 million yuan [2] - The shareholder and its concerted parties have a total of 47,420,836 shares maturing within one year, which is 70.67% of their holdings and 46.09% of the total share capital, with a financing balance of 48.9 million yuan [2] Group 2 - The shareholder and its concerted parties do not have any non-operating fund occupation or illegal guarantees that would harm the interests of the listed company [3] - The share pledge does not impact the company's operations, governance, or financial stability, and there are no obligations for major asset restructuring or performance compensation [3] - The financial status of the shareholder is good, and there is no risk of forced liquidation or transfer of pledged shares [4]

恩威医药公告，控股股东成都恩威投资（集团）有限公司解除质押300万股，占其持股11.66%、占公司 总股本2.92%，质押起始日2025/8/18，解除日2026/2/4，质权人为徐英壮。恩威集团持股2573.32万股， 占25.01%。本次解除后其累计质押2238万股，占持股86.97%、占总股本21.75%。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2026-005 恩威医药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 恩威医药股份有限公司（以下简称"公司"、"本公司"）近日接到控股股 东成都恩威投资（集团）有限公司（以下简称"恩威集团"）函告，获悉恩威集 团所持本公司的部分股份被办理了解除质押。恩威集团为公司控股股东，持有公 司 25,733,200 股，占公司总股本的 25.01%。具体事项如下： 2、股东股份累计质押情况 1 股东 名称 是否为控股股东 或第一大股东及 其一致行动人 本次解除 质押数量 （股） 占其所 持股份 比例 占公司 总股本 比例 质押 起始 日 质押 解除 日 质权人 质押 用途 恩威 集团 是 3,000,000 11.66% 2.92% 2025 /8/18 2026 /2/4 徐英壮 自身 生产 经营 合计 - 3,000,000 - 2.92% - - - - 1、本次股东股份解除质押基本情况 截至公告披露日，上述股东及其一致行动人所持质 ...

Summary of Key Points Core Viewpoint The article discusses the share transfer process of Enwei Pharmaceutical Co., Ltd. (恩威医药) through a price inquiry method, detailing the procedures, pricing, and compliance with regulatory requirements. Group 1: Inquiry Transfer Overview - The inquiry transfer involves the transfer of 4,000,000 shares, representing 3.89% of the company's total share capital, with a transfer price set at 26.54 yuan per share, totaling 106,160,000 yuan [10][20][22]. - The transfer was conducted by CITIC Securities, which acted as the organizing broker for the inquiry transfer [1][21]. Group 2: Pricing and Allocation Principles - The price floor for the inquiry transfer was determined to be no less than 70% of the average trading price of Enwei Pharmaceutical shares over the 20 trading days prior to January 26, 2026 [3][27]. - The allocation of shares was based on a priority system that favored higher subscription prices, followed by subscription quantities and the order of receipt of subscription forms [4][5]. Group 3: Compliance and Regulatory Adherence - The inquiry transfer process was confirmed to be legal and compliant with various regulations, including the Company Law and Securities Law of the People's Republic of China [11][17]. - CITIC Securities conducted a thorough qualification review of both the transferor and transferee, ensuring that all parties met the necessary criteria for participation in the inquiry transfer [14][15]. Group 4: Investor Participation - A total of 451 institutional investors received the subscription invitation, including 80 fund companies, 54 securities firms, and 250 private fund managers [7][28]. - The inquiry transfer received 32 valid subscription forms during the designated period, indicating strong interest from institutional investors [8][28]. Group 5: Conclusion and Future Implications - The transfer will not change the controlling shareholder or the actual controller of Enwei Pharmaceutical, ensuring stability in the company's governance structure [20][32]. - The shares acquired through this inquiry transfer are subject to a six-month lock-up period, preventing immediate resale by the investors [20][32].

Core Viewpoint - Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties have reduced their shareholding in Enwei Pharmaceutical Co., Ltd. from 69.10% to 65.22% through a non-public transfer of 4,000,000 shares at a price of 26.54 yuan per share, totaling 106,160,000 yuan, without affecting the company's control structure or governance [3][4][9]. Group 1 - The equity change involves Chengdu Enwei Investment (Group) Co., Ltd. and its acting-in-concert parties, which collectively held over 5% of Enwei Pharmaceutical's shares. The shareholding ratio decreased from 69.10% to 65.22% after the transfer [3][9]. - The transfer method was a non-public inquiry transfer, and it did not trigger a mandatory tender offer. The shares acquired through this transfer cannot be transferred for six months [3][4][15]. - The total number of shares transferred was 4,000,000, representing 3.89% of the company's total share capital, with a transaction price of 26.54 yuan per share [4][12]. Group 2 - The inquiry transfer was organized by CITIC Securities, which confirmed that the process adhered to relevant regulations and was conducted fairly and transparently [14][32]. - A total of 451 institutional investors received the subscription invitation, and 32 valid subscription bids were received during the designated time [22][24]. - The final allocation resulted in 11 institutional investors receiving shares, confirming the transfer price and quantity as per the established rules [25][26].